Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
Cibil Report
Get cibil report
My Account
Log In
Log into your account
Offers
Check out pre-approved offers now!
Languages
Chosen Language: English
Do Not Call
Do not call
En
Wockhardt Ltd. Share Price
N/A
1D
1M
3M
6M
1Y
5Y
Day's Range
Low
₹1,858.20
High
₹1,913.70
Price Summary
| Previous Close | ₹1,886.40 |
|---|---|
| Day's Range | ₹1,858.20 - ₹1,913.70 |
| Open | ₹1,875.00 |
| 52 Week Range | ₹1,086.70 - ₹2,422.30 |
| Volume | 3,53,166 |
| Market Cap | ₹0.03 |
| Previous Close | ₹1,888.00 |
|---|---|
| Day's Range | ₹1,867.70 - ₹1,911.70 |
| Open | ₹1,868.35 |
| 52 Week Range | ₹1,086.80 - ₹2,420.00 |
| Volume | 28,385 |
| Market Cap | ₹0.03 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 6,662.12 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 74.06 |
| TTM EPS (₹) | 25.23 |
| P/E Ratio | 89.54 |
| Book Value(₹) | 5.89 |
| PAT Margin (%) | 5.13 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 6.79 |
| Trade Value ( ₹ in Lacs) | 535.91 |
|---|---|
| Market Cap (₹ in Mn) | 0.03 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 74.06 |
| TTM EPS (₹) | 25.23 |
| P/E Ratio | 89.54 |
| Book Value(₹) | 5.89 |
| PAT Margin (%) | 5.13 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 6.79 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 7820.0 | 14020.0 |
| Expenses | N/A | N/A |
| PBT | 910.0 | -120.0 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 820.0 | -120.0 |
About Wockhardt Ltd.
| Founded | 1999 |
|---|---|
| Managing Director | Murtaza Khorakiwala |
| NSE Symbol | WOCKPHARMA |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,25,150.16 | 1,776.00 | 1,583.70 - 1,583.70 |
| Divi's Laboratories Ltd. | 2,66,264.99 | 10,006.50 | 5,647.50 - 5,647.50 |
| Torrent Pharmaceuticals Ltd. | 1,76,300.50 | 4,691.65 | 3,532.60 - 3,532.60 |
| Laurus Labs Ltd. | 1,25,352.43 | 2,304.25 | 917.95 - 917.95 |
| Zydus Lifesciences Ltd. | 1,23,590.72 | 1,197.05 | 835.50 - 835.50 |
| Apollo Hospitals Enterprise Ltd. | 1,21,411.76 | 8,534.50 | 6,696.50 - 6,696.50 |
| Lenskart Solutions Ltd. | 1,16,724.84 | 686.40 | 0.00 - 0.00 |
| Dr. Reddy's Laboratories Ltd. | 1,14,351.20 | 1,366.10 | 1,101.00 - 1,101.00 |
| Cipla Ltd. | 1,12,474.18 | 1,395.80 | 1,165.70 - 1,165.70 |
| Mankind Pharma Ltd. | 1,02,315.40 | 2,523.70 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Nov
4
2026
Posted on Nov 4th 2026
Shelter Pharma informs about board meeting
Shelter Pharma has informed that the meeting of the Board of Directors of the Company will be held on Saturday, 07th November, 2026, at corporate office of the company at 5TH Floor, 501 SAKAR 4, Opp. Town Hall, Ashram Road, Ahmedabad, Gujarat -380006, to consider, approve and take on record the Un-audited Financial Results for the Half year ended on September 30, 2026 as per Regulation 33 of the SEBI (LODR) Regulation, 2015 along with Limited Review report on above Financial Results; Such Other agendas as may be considered necessary with the permission of the chair.
The above information is a part of company’s filings submitted to BSE.
Read More
Nov
4
2026
Posted on Nov 4th 2026
Kopran - Quaterly Results
The Total revenue for the quarter ended September 2026 of Rs. 871.18 millions grew by 105.52% from Rs. 423.89 millions.The Total Profit for the quarter ended September 2026 of Rs. 62.85 millions grew from Rs.-39.93 millions Operating profit Margin for the quarter ended September 2026 improved to 111.81% as compared to -28.83% of corresponding quarter ended September 2025
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 871.18 | 423.89 | 105.52 | 1498.76 | 937.24 | 59.91 | 3056.46 | 2710.10 | 12.78 |
| Other Income | 8.61 | 3.23 | 166.56 | 37.75 | 21.21 | 77.98 | 19.99 | 59.04 | -66.14 |
| PBIDT | 111.81 | -28.83 | -487.83 | 225.49 | 39.85 | 465.85 | 495.75 | 445.60 | 11.25 |
| Interest | 13.86 | 8.25 | 68.00 | 26.24 | 18.67 | 40.55 | 42.00 | 37.66 | 11.52 |
| PBDT | 97.95 | -37.08 | -364.16 | 199.25 | 21.18 | 840.75 | 453.75 | 407.94 | 11.23 |
| Depreciation | 13.86 | 11.62 | 19.28 | 27.34 | 23.81 | 14.83 | 49.81 | 49.99 | -0.36 |
| PBT | 84.09 | -48.70 | -272.67 | 171.91 | -2.63 | -6636.50 | 403.94 | 357.95 | 12.85 |
| TAX | 21.24 | -8.77 | -342.19 | 41.85 | 2.12 | 1874.06 | 99.94 | 89.38 | 11.81 |
| Deferred Tax | 1.78 | 2.03 | -12.32 | 3.06 | 2.12 | 44.34 | 9.58 | 3.06 | 213.07 |
| PAT | 62.85 | -39.93 | -257.40 | 130.06 | -4.75 | -2838.11 | 304.00 | 268.57 | 13.19 |
| Equity | 483.26 | 482.86 | 0.08 | 483.26 | 482.86 | 0.08 | 482.86 | 482.86 | 0.00 |
| PBIDTM(%) | 12.83 | -6.80 | -288.70 | 15.05 | 4.25 | 253.85 | 16.22 | 16.44 | -1.35 |
Read More
Nov
4
2026
Posted on Nov 4th 2026
Neuland Laboratories - Quaterly Results
The sales slipped to Rs. 4496.57 millions for the September 2026 quarter as against Rs. 5142.73 millions during the year-ago period.A big decline of -47.00% was reported for the quarter ended September 2026 to Rs. 511.28 millions from Rs. 964.60 millions of corresponding previous quarter.Operating Profit reported a sharp decline to 1045.54 millions from 1569.22 millions in the corresponding previous quarter.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 4496.57 | 5142.73 | -12.56 | 10912.34 | 8070.26 | 35.22 | 20229.85 | 14768.37 | 36.98 |
| Other Income | 74.93 | 17.99 | 316.51 | 159.85 | 96.55 | 65.56 | 301.64 | 205.09 | 47.08 |
| PBIDT | 1045.54 | 1569.22 | -33.37 | 3356.23 | 1990.71 | 68.59 | 6034.09 | 3428.08 | 76.02 |
| Interest | 73.05 | 53.41 | 36.77 | 142.77 | 99.24 | 43.86 | 239.45 | 82.96 | 188.63 |
| PBDT | 972.49 | 1515.81 | -35.84 | 3213.46 | 1891.47 | 69.89 | 5794.64 | 4109.16 | 41.02 |
| Depreciation | 287.68 | 225.39 | 27.64 | 553.29 | 427.26 | 29.50 | 917.30 | 655.42 | 39.96 |
| PBT | 684.81 | 1290.42 | -46.93 | 2660.17 | 1464.21 | 81.68 | 4877.34 | 3453.74 | 41.22 |
| TAX | 173.53 | 325.82 | -46.74 | 675.27 | 362.53 | 86.27 | 1246.29 | 859.48 | 45.01 |
| Deferred Tax | -5.15 | 0.70 | -835.71 | -12.21 | -6.26 | 95.05 | -42.55 | 122.95 | -134.61 |
| PAT | 511.28 | 964.60 | -47.00 | 1984.90 | 1101.68 | 80.17 | 3631.05 | 2594.26 | 39.96 |
| Equity | 129.00 | 129.01 | -0.01 | 129.00 | 129.01 | -0.01 | 129.00 | 129.00 | 0.00 |
| PBIDTM(%) | 23.25 | 30.51 | -23.80 | 30.76 | 24.67 | 24.69 | 29.83 | 23.21 | 28.50 |
Read More
Nov
4
2026
Posted on Nov 4th 2026
Hikal - Quaterly Results
The sales for the September 2026 quarter moved up 36.33% to Rs. 4342.00 millions as compared to Rs. 3185.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2026 is Rs. -62.00 millions as compared to Net Loss of Rs. -347.00 millions of corresponding quarter ended September 2025Operating profit for the quarter ended September 2026 rose to 465.00 millions as compared to 93.00 millions of corresponding quarter ended September 2025.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 4342.00 | 3185.00 | 36.33 | 8370.00 | 6989.00 | 19.76 | 17126.00 | 18598.00 | -7.91 |
| Other Income | 17.00 | 19.00 | -10.53 | 35.00 | 29.00 | 20.69 | 123.00 | 50.00 | 146.00 |
| PBIDT | 465.00 | 93.00 | 400.00 | 852.00 | 351.00 | 142.74 | 2328.00 | 3335.00 | -30.19 |
| Interest | 134.00 | 149.00 | -10.07 | 283.00 | 320.00 | -11.56 | 621.00 | 752.00 | -17.42 |
| PBDT | 331.00 | -56.00 | -691.07 | 658.00 | 31.00 | 2022.58 | 856.00 | 2583.00 | -66.86 |
| Depreciation | 417.00 | 412.00 | 1.21 | 844.00 | 806.00 | 4.71 | 1638.00 | 1344.00 | 21.88 |
| PBT | -86.00 | -468.00 | -81.62 | -186.00 | -775.00 | -76.00 | -782.00 | 1239.00 | -163.12 |
| TAX | -24.00 | -121.00 | -80.17 | -49.00 | -201.00 | -75.62 | -295.00 | 330.00 | -189.39 |
| Deferred Tax | -24.00 | -121.00 | -80.17 | -49.00 | -201.00 | -75.62 | -275.00 | 30.00 | -1016.67 |
| PAT | -62.00 | -347.00 | -82.13 | -137.00 | -574.00 | -76.13 | -487.00 | 909.00 | -153.58 |
| Equity | 247.00 | 247.00 | 0.00 | 247.00 | 247.00 | 0.00 | 247.00 | 247.00 | 0.00 |
| PBIDTM(%) | 10.71 | 2.92 | 266.77 | 10.18 | 5.02 | 102.68 | 13.59 | 17.93 | -24.19 |
Read More
Nov
4
2026
Posted on Nov 4th 2026
Emcure Pharma - Quaterly Results
The sales moved up 32.32% to Rs. 16679.84 millions for the September 2026 quarter as compared to Rs. 12606.04 millions during the year-ago period.Net Profit witnessed a 111.21% growth almost the double from Rs. 1176.22 millions to Rs. 2484.28 millions of same quarter last year.Operating profit surged to 4298.06 millions from the corresponding previous quarter of 2473.44 millions.
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202609 | 202509 | % Var | 202609 | 202509 | % Var | 202603 | 202503 | % Var | |
| Sales | 16679.84 | 12606.04 | 32.32 | 31189.15 | 23571.77 | 32.32 | 52431.88 | 43819.24 | 19.65 |
| Other Income | 335.38 | 227.53 | 47.40 | 585.70 | 442.77 | 32.28 | 2095.16 | 1188.07 | 76.35 |
| PBIDT | 4298.06 | 2473.44 | 73.77 | 7944.21 | 4968.68 | 59.89 | 13342.66 | 7656.44 | 74.27 |
| Interest | 324.20 | 277.14 | 16.98 | 651.96 | 482.52 | 35.12 | 1182.71 | 1129.62 | 4.70 |
| PBDT | 3973.86 | 2196.30 | 80.93 | 7292.25 | 4451.16 | 63.83 | 11909.24 | 6526.82 | 82.47 |
| Depreciation | 650.10 | 617.39 | 5.30 | 1281.76 | 1215.56 | 5.45 | 2467.33 | 2249.72 | 9.67 |
| PBT | 3323.76 | 1578.91 | 110.51 | 6010.49 | 3235.60 | 85.76 | 9441.91 | 4277.10 | 120.75 |
| TAX | 839.48 | 402.69 | 108.47 | 1525.13 | 831.49 | 83.42 | 2112.32 | 1105.82 | 91.02 |
| Deferred Tax | -29.82 | -57.13 | -47.80 | -47.64 | -68.36 | -30.31 | -225.09 | -21.25 | 959.25 |
| PAT | 2484.28 | 1176.22 | 111.21 | 4485.36 | 2404.11 | 86.57 | 7329.59 | 3171.28 | 131.12 |
| Equity | 1897.11 | 1895.65 | 0.08 | 1897.11 | 1895.65 | 0.08 | 1895.90 | 1894.83 | 0.06 |
| PBIDTM(%) | 25.77 | 19.62 | 31.33 | 25.47 | 21.08 | 20.84 | 25.45 | 17.47 | 45.64 |
Read More
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Wockhardt Ltd. is ₹1,886.40 as of 2026-11-04.
The market capitalisation of Wockhardt Ltd. is ₹30,362.96 as of 2026-11-03.
The 1-year return of Wockhardt Ltd. is 472.60% as of 2026-11-04.
The P/E ratio of Wockhardt Ltd. is 89.54 as of 2026-11-04.
The 52-week high and low of Wockhardt Ltd. are ₹2,422.30 and ₹1,086.70, respectively, as of 2026-11-04.
View More
People Also Ask
Wockhardt Ltd. offers branded generics, biopharmaceuticals and novel antibiotics in areas like cardiology, diabetology, gastroenterology and infectious diseases, with operations across India, the UK and emerging markets.
Wockhardt Ltd. partners through hospital‑focused product portfolios, licensing, contract manufacturing and supplying critical‑care and acute‑care drugs in multiple geographies.
View More
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
Home
Shopping
Loan Offers
My Accounts
Explore
